Our previous study demonstrated that TMEM16A was an essential component of CaCC in hepatocytes and increased during nonalcoholic fatty liver disease [9], indicating the involvement of TMEM16A in liver-related disease. Here, ANO1 is linked to metabolic dysfunction-associated steatotic liver disease.